Suppr超能文献

恶性胶质瘤的动脉内化疗与放疗联合应用

Combined intra-arterial chemotherapy and irradiation of malignant gliomas.

作者信息

Watne K, Nome O, Hager B, Hirschberg H

机构信息

Department of Medical Oncology, Norwegian Radium Hospital, Oslo.

出版信息

Acta Oncol. 1991;30(7):835-41. doi: 10.3109/02841869109091831.

Abstract

Seventy-nine patients with malignant gliomas (19 anaplastic astrocytomas and 60 glioblastoma multiforme) received 4 cycles of infra-ophthalmic carotid injection of 160 mg carmustine, 2 mg vincristine IV and procarbazine orally 50 mg 3 times daily for 1 week, followed by whole-brain irradiation, with a midpoint dose of 54 Gy/6 weeks. Response, judged by CT-scan, was seen in 31 out of 57 evaluable patients with a median survival of 30 months and 40% survival at 3 years. In all patients who responded to the treatment, a tumour regression was seen on CT-scan after chemotherapy before irradiation. In the 26 patients with progressive disease under chemotherapy, the median survival was 5 months. None of the patients who had progressive disease during chemotherapy had benefit from irradiation. The most important prognostic factors were good pretreatment performance status, glucocorticoid dependency and age. Few serious side-effects of the angiographic procedure were seen. Leukoencephalopathy was not observed in this study.

摘要

79例恶性胶质瘤患者(19例间变性星形细胞瘤和60例多形性胶质母细胞瘤)接受了4个周期的眶下颈动脉注射160毫克卡莫司汀、静脉注射2毫克长春新碱以及口服丙卡巴肼(每日3次,每次50毫克,共1周),随后进行全脑照射,中点剂量为54 Gy/6周。通过CT扫描判断,57例可评估患者中有31例有反应,中位生存期为30个月,3年生存率为40%。在所有对治疗有反应的患者中,放疗前化疗后CT扫描可见肿瘤缩小。在化疗期间病情进展的26例患者中,中位生存期为5个月。化疗期间病情进展的患者均未从放疗中获益。最重要的预后因素是治疗前良好的身体状况、糖皮质激素依赖和年龄。血管造影术的严重副作用少见。本研究未观察到白质脑病。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验